In 2025, regenerative medicine is making strides in treating pet diseases, particularly with stem cell therapies. Gallant, a biotech company, is at the forefront, focusing on ready-to-use stem cell therapies for pets.
In June 2025, Gallant closed an $18 million Series B funding round, led by Digitalis Ventures. This investment will accelerate the commercialization of its stem cell therapy for feline chronic refractory stomatitis (FCGS), with FDA approval expected in early 2026.
This could be the first FDA-approved allogeneic stem cell therapy for veterinary use. Gallant is also developing therapies for canine and feline osteoarthritis, atopic dermatitis, and chronic kidney disease. To boost its veterinary education efforts, Gallant appointed Dr. Rebecca Windsor as Director of Veterinary Affairs.